Send Inquiry

Request To Call Back

Mabtas 500

Name: Mabtas 500
Brand: ONCOTRUST
Price: 5500.0 INR
Availability: InStock

Price 5500.0 INR/ Piece

Get a Price/Quote

MOQ : 1 Piece

Mabtas 500 Specification

Salt Composition
Rituximab (500mg)

Indication
Non-Hodgkins lymphoma, Chronic lymphocytic leukemia, Rheumatoid arthritis

Dosage Form
Injection (Vial)

Feature
Chimeric monoclonal antibody, anti-CD20

Ingredients
Rituximab, excipients

Application
Administered via intravenous infusion under medical supervision

Ph Level
6.5 - 7.0

Temperature Needed For Fermentation
28 Celsius (oC)

Physical Color/Texture
Clear, colorless to pale yellow solution

Fermentation Smell
Odorless

Storage Instructions
Store at 2C - 8C. Do not freeze. Protect from light.

Shelf Life
24 Hours

Stability After Dilution
Stable for up to 24 hours at 2C-8C after dilution in infusion bags

Compatibility
Dilute in 0.9% Sodium Chloride or 5% Dextrose before use

Strength
500 mg/50 ml vial

Storage Precautions
Do not shake. Keep out of reach of children.

Prescription
Prescription only medication

Usage Restriction
For hospital/qualified healthcare use only

Packaging Size
1 vial per pack

Administration Route
Intravenous

Container Type
Glass vial with rubber stopper and aluminium seal

Mabtas 500 Trade Information

Minimum Order Quantity
1 Piece

Delivery Time
24 Hours

About Mabtas 500

Mabtas 500 Injection is a targeted monoclonal antibody used in the treatment of HER2-positive breast cancer and gastric (stomach) cancer. It contains Trastuzumab 500 mg, which works by specifically targeting the HER2 protein present on cancer cells, thereby slowing or stopping their growth.

Key Benefits

Effective in treating HER2-positive breast cancer
Used in metastatic and early-stage cancer therapy
Helps inhibit the growth and spread of cancer cells
Targeted therapy with proven clinical efficacy

Indications

HER2-positive Breast Cancer
HER2-positive Gastric Cancer

Storage Instructions

Store in a refrigerator at 2C to 8C
Do not freeze
Protect from light

Safety Information

To be administered under the supervision of a qualified oncologist
Dosage and treatment schedule should be decided by a healthcare professional
Monitor cardiac function during treatment as advised

Targeted Therapy for Hematological Disorders

Mabtas 500 offers a powerful, targeted treatment option for patients with Non-Hodgkin's lymphoma, Chronic lymphocytic leukemia, and Rheumatoid arthritis. Its mechanism of action involves precise targeting of B-cells, aiding in the management of these serious conditions. Exclusive administration by trained professionals ensures patient safety and optimized outcomes.

Strict Storage and Handling Guidelines

The efficacy of Mabtas 500 depends on correct storage and dilution. It must be kept at 2C-8C, shielded from light, and never frozen or shaken. After dilution, the solution remains stable for up to 24 hours when refrigerated. Such precautions help maintain the medication's integrity from packaging to administration.

FAQ's of Mabtas 500:

Q: How should Mabtas 500 be administered?

A: Mabtas 500 is administered as an intravenous infusion in a hospital setting or under the supervision of qualified healthcare personnel. It must be diluted in 0.9% Sodium Chloride or 5% Dextrose before infusion.

Q: What precautions should be taken during storage and preparation of Mabtas 500?

A: Store Mabtas 500 at 2C-8C, protect from light, and do not freeze or shake the vial. After dilution, use within 24 hours if refrigerated. Always keep it out of the reach of children.

Q: When and why is Mabtas 500 prescribed?

A: Mabtas 500 is indicated for Non-Hodgkin's lymphoma, Chronic lymphocytic leukemia, and Rheumatoid arthritis. It is prescribed when a monoclonal antibody therapy targeting CD20-positive cells is necessary to manage these conditions.

Q: Where can Mabtas 500 be used?

A: This product is specifically restricted for use in hospitals or by qualified healthcare providers. Self-administration is not permitted due to the need for expert monitoring during infusion.

Q: What are the benefits of Mabtas 500 treatment?

A: Mabtas 500 provides targeted therapy, effectively reducing malignant or diseased B-cells while minimizing impact on healthy cells. Its selective mechanism contributes to better outcomes for patients with certain cancers and autoimmune disorders.

Q: How is the solution prepared for infusion?

A: The contents of the vial must be diluted aseptically into an infusion bag containing either 0.9% Sodium Chloride or 5% Dextrose. The prepared solution should appear clear and colorless to pale yellow before administration.

Tell us about your requirement